Biopharma Industry Struggles Amid Pandemic Fallout

Biopharma Industry Struggles Amid Pandemic Fallout

Liliana Cruz
1 min read

Biomanufacturing Challenges Persist Amid COVID-19 Fallout

Biomanufacturing, crucial in the production of biopharmaceuticals, continues to face resilience, supply chain, and talent acquisition hurdles amid the pandemic's aftermath. A survey by Cytiva across 22 countries uncovered a decline in perceived resilience within the biopharmaceutical industry's R&D ecosystem. Despite this, there's a steadfast commitment to enhancing local R&D systems' resilience.

Key Takeaways

  • Biopharma leaders prioritize resilience but struggle to embed it into operations
  • Only 13% believe their supply chains have become more robust
  • Talent acquisition and retention pose significant challenges in the biomanufacturing sector
  • US-based biopharma firms experienced a 46% funding decline between 2021 and 2022
  • Global disparities persist in vaccine manufacturing and R&D funding allocation


The sector's struggles with resilience, supply chain robustness, and talent acquisition pose hurdles exacerbated by funding drops and regional disparities. These challenges not only impede rapid responses to health crises but also hinder long-term innovation and global preparedness. Essential measures include enhanced collaboration and strategic funding allocations to drive future breakthroughs.

Did You Know?

  • Biomanufacturing: It involves using biological systems to produce industrial products, including vaccines and therapeutic proteins vital for public health.
  • Resilience in Biopharmaceutical Industry: Refers to the industry's ability to withstand and recover quickly from disruptions, ensuring stability and reliability of pharmaceutical supply chains.
  • Pandemic Treaty: A proposed international agreement to improve global preparedness and response to future health crises.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines. The cover photo is computer generated art for illustrative purposes only; not indicative of factual content. If you believe this article infringes upon copyright rights, please do not hesitate to report it by sending an email to us. Your vigilance and cooperation are invaluable in helping us maintain a respectful and legally compliant community.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings